Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

La descripción de la empresa se muestra en inglés.

Visitar sitio web →

Estadísticas Clave

Capitalización: $2.79B
Ratio P/E: N/A
Máximo 52 Sem.: $28.23
Mínimo 52 Sem.: $19.01
Volumen Promedio: 997.57K

Datos proporcionados por Yahoo Finance a través de yfinance. Actualizado diariamente.

Información de la Empresa

Industria: Biotecnología
Bolsa: NASDAQ
País: United States
Empleados: 145